Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human-Reference-Cited by-同舟云学术

Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human

Published:2011-12-06 Issue:1 Volume:39 Page:67-86
ISSN:1567-567X
Container-title:Journal of Pharmacokinetics and Pharmacodynamics
language:en
Short-container-title:J Pharmacokinet Pharmacodyn

Author:

Shah Dhaval K.,Betts Alison M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s10928-011-9232-2.pdf

Reference70 articles.

1. Levy G (1966) Kinetics of pharmacologic effects. Clin Pharmacol Ther 7:362–372

2. Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645–2668

3. Wang W, Wang EQ, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84:548–558

4. Mould DR, Sweeney KR (2007) The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 10:84–96

5. Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507–532

Cited by 380 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PBPK model of pegylated liposomal doxorubicin to simultaneously predict the concentration–time profile of encapsulated and free doxorubicin in tissues;Drug Delivery and Translational Research;2024-08-05

2. Physiologically Based Pharmacokinetic Model of OATP1B Substrates with a Nonlinear Mixed Effect Approach: Estimating Empirical In Vitro-to-In Vivo Scaling Factors;Clinical Pharmacokinetics;2024-08

3. Exploring How Antibody Format Drives Clearance from the Brain;Molecular Pharmaceutics;2024-07-26

4. Determining tissue distribution of the oral antileishmanial agent miltefosine: a physiologically-based pharmacokinetic modeling approach;Antimicrobial Agents and Chemotherapy;2024-07-09

5. Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling;Antibodies;2024-07-09